Evidence map›Paper›PMID 37836350›Full record

ArticleNanomaterials (Basel, Switzerland)2023

Alginate Microsponges as a Scaffold for Delivery of a Therapeutic Peptide against Rheumatoid Arthritis.

Daniela Ariaudo, Francesca Cavalieri, Antonio Rinaldi, Ana Aguilera, Matilde Lopez, Hilda Garay Perez, Ariel Felipe, Maria Del Carmen Dominguez, Odalys Ruiz, Gillian Martinez and 1 more

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Microsponge Drug Delivery Systems: Advancing the Therapeutic Efficacy of Anti-Inflammatory Medications.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daniela AriaudoDepartment of Chemical Science and Technologies, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy.
Francesca CavalieriDepartment of Chemical Science and Technologies, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy.ORCID 0000-0001-5391-5069
Antonio RinaldiPROMAS-MATPRO Laboratory, Sustainability Department, ENEA, 00123 Rome, Italy.ORCID 0000-0002-3087-2649
Ana AguileraBiotechnological Development Direction, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.ORCID 0000-0002-1983-4684
Matilde LopezBiotechnological Development Direction, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Hilda Garay PerezBiomedical Research Direction, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Ariel FelipeBiomedical Research Direction, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.ORCID 0009-0005-9012-2531
Maria Del Carmen DominguezBiomedical Research Direction, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Odalys RuizBiotechnological Development Direction, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.
Gillian MartinezBusiness Development Direction, Center for Genetic Engineering and Biotechnology, Avenue 31/158 and 190, Playa, Havana 11600, Cuba.
Mariano VenanziDepartment of Chemical Science and Technologies, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133 Rome, Italy.ORCID 0000-0001-9364-7441

Funding

European Union Horizon 2020 Research and Innovation Program 872233
6 · The paper itself

Abstract

The quest for biocompatible drug-delivery devices that could be able to open new administration routes is at the frontier of biomedical research. In this contribution, porous polysaccharide-based microsponges based on crosslinked alginate polymers were developed and characterized by optical spectroscopy and nanoscopic microscopy techniques. We show that macropores with a size distribution ranging from 50 to 120 nm enabled efficient loading and delivery of a therapeutic peptide (CIGB814), presently under a phase 3 clinical trial for the treatment of rheumatoid arthritis. Alginate microsponges showed 80% loading capacity and sustained peptide release over a few hours through a diffusional mechanism favored by partial erosion of the polymer scaffold. The edible and biocompatible nature of alginate polymers open promising perspectives for developing a new generation of polysaccharide-based carriers for the controlled delivery of peptide drugs, exploiting alternative routes with respect to intravenous administration.

Indexed as

alginateCIGB814drug deliverypolysaccharide microspongesrheumatoid arthritistherapeutic peptides

Identifiers

PMID37836350
PMCPMC10574729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.